2.79
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AIM ImmunoTech Inc | AIM | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Previous Close | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 2.79 | 0.00 | 0.00 | 0.00 | 2.79 | 20:00:00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.79 | USD |
AIM ImmunoTech Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 91.02M | 32.62M | 2.30M | $ 140.00k | $ - | -9.56 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 2.40M | $ - | 0.00% | 24.00 | 37.40% |
AIM ImmunoTech News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AIM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.13 | 3.20 | 2.67 | 2.86 | 4,535,896 | -0.34 | -10.86% |
| 1 Month | 2.57 | 4.30 | 2.41 | 3.16 | 9,043,199 | 0.22 | 8.56% |
| 3 Months | 2.49 | 4.30 | 2.16 | 2.90 | 6,184,301 | 0.30 | 12.05% |
| 6 Months | 1.07 | 8.75 | 0.78 | 3.07 | 7,239,466 | 1.72 | 160.75% |
| 1 Year | 1.96 | 8.75 | 0.381 | 2.85 | 4,381,011 | 0.83 | 42.35% |
| 3 Years | 1.96 | 8.75 | 0.381 | 2.85 | 4,381,011 | 0.83 | 42.35% |
| 5 Years | 1.96 | 8.75 | 0.381 | 2.85 | 4,381,011 | 0.83 | 42.35% |
AIM ImmunoTech Description
| AIM ImmunoTech Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States. |
